LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said it candidate vaccine, M72/AS01E, was shown to significantly reduce pulmonary tuberculosis in adults with latent tuberculosis infections.
The results form part of the pharmaceutical giant's ongoing phase two b clinical trial testing.
"This ground-breaking study shows – for the first time – that a subunit vaccine can significantly reduce the incidence of pulmonary tuberculosis in healthy, HIV-negative adults with latent tuberculosis infection, and that more effective vaccines against tuberculosis are achievable," said Jacqui Shea, chief executive of Aeras, which contributed to the partnership.
"Given the overwhelming public health need, the importance of these promising results, which need to be confirmed through additional clinical research, cannot be overstated. An effective vaccine, able to reduce transmission, would be by far the most impactful new intervention to end the global tuberculosis epidemic," Shea added.